tolllik
receptor
tlr
sentinel
receptor
host
innat
immun
system
recogn
conserv
pathogenassoci
molecular
pattern
invad
microb
includ
virus
activ
tlr
establish
antivir
innat
immun
respons
coordin
develop
longlast
adapt
immun
order
control
viral
pathogenesi
howev
microbeinduc
damag
host
tissu
may
releas
dangerassoci
molecular
pattern
also
activ
tlr
lead
overexuber
inflammatori
respons
ultim
tissu
damag
thu
tlr
proven
promis
target
therapeut
treatment
viral
infect
result
inflammatori
damag
adjuv
order
enhanc
efficaci
vaccin
explor
recent
advanc
tlr
biolog
focu
novel
drug
target
tlr
agonist
antagonist
antivir
therapi
futur
scienc
group
prr
recogn
molecular
structur
microorgan
link
innat
adapt
immun
respons
two
import
discoveri
strengthen
janeway
concept
prr
proof
import
tollmedi
signal
induct
antifung
peptid
drosophila
respons
infect
posit
clone
lp
gene
known
mice
shown
express
mutat
gene
led
lp
hyporespons
two
strain
import
research
result
share
nobel
prize
physiolog
medicin
among
variou
famili
prr
eg
tolllik
receptor
tlr
nodlik
receptor
rigilik
receptor
rlr
ctype
lectin
receptor
cytosol
dna
receptor
tlr
one
largest
beststudi
famili
prr
studi
tlr
biolog
provid
molecular
insight
prr
recogn
pamp
damp
lead
activ
signal
cascad
converg
order
induc
express
proinflammatori
cytokin
chemokin
antivir
interferon
ifn
moreov
discoveri
tlr
also
enabl
identif
famili
innat
immun
receptor
review
togeth
knowledg
gener
field
tlr
past
decad
result
signific
paradigm
shift
understand
innat
immun
role
develop
longlast
pathogenspecif
adapt
immun
respons
review
articl
briefli
summar
current
advanc
field
tlr
signal
might
target
tlr
signal
order
mitig
diseas
enhanc
specif
immun
evid
thu
far
point
role
tlr
immun
inflammatori
diseas
includ
allergi
autoimmun
disord
cancer
review
date
mani
virus
shown
activ
innat
immun
system
tlr
assign
tlr
import
role
control
viral
infect
review
follow
section
provid
exampl
tlrviru
interact
outcom
well
recent
advanc
understand
role
tlr
antivir
innat
immun
focu
studi
design
develop
novel
tlrtarget
drug
exert
antivir
activ
serv
adjuv
vaccin
tlr
evolutionarili
conserv
across
wide
rang
speci
human
mous
tlr
identifi
tlr
type
transmembran
protein
compos
ntermin
leucinerich
repeat
lrr
domain
enabl
recognit
wide
varieti
ligand
singl
transmembranespan
domain
conserv
cytoplasm
receptor
resist
tir
domain
downstream
signal
transduct
review
resolut
crystal
structur
reveal
horseshoeshap
antigen
bind
core
form
lrrcontain
domain
sequenc
homolog
analys
indic
activ
tlr
requir
common
tertiari
structur
ten
function
human
tlr
function
mous
tlr
categor
subcellular
local
local
cell
surfac
wherea
resid
endosom
andor
endoplasm
reticulum
review
tlr
form
homodim
ligand
bind
lrr
howev
typic
form
heterodim
either
possibl
detect
compon
microbi
cell
wall
membran
lipopeptid
peptidoglycan
porin
mannan
heterodimer
order
bind
profilin
protein
parasit
toxoplasma
gondii
recogn
lp
gramneg
bacteria
fusion
f
protein
respiratori
syncyti
viru
rsv
mous
mammari
tumor
viru
ebola
viru
glycoprotein
addit
also
sens
damp
includ
oxid
host
oxid
phospholipid
produc
due
oxid
stress
respons
acut
lung
injuri
acid
aspir
infect
respiratori
virus
bacteria
exposur
microbi
product
chromatin
bind
protein
releas
upon
pyroptosi
detect
flagellin
major
protein
bacteri
flagella
wherea
ligand
yet
identifi
review
homodim
mous
recogn
compon
uropathogen
escherichia
coli
sens
microbi
nucleic
acid
dsrna
sens
ssrna
unmethyl
cpg
dna
sens
moreov
mous
recogn
bacteri
ribosom
rna
futur
scienc
group
wwwfuturemedicinecom
extent
requir
coreceptor
molecul
order
recogn
microbi
ligand
noncoval
associ
protein
confer
lp
respons
bind
lipid
region
lp
deep
hydrophob
pocket
interact
ectodomain
suggest
complex
essenti
ligand
second
coreceptor
transfer
lp
monom
increas
respons
cell
lp
low
concentr
f
protein
rsv
also
requir
signal
event
involv
direct
proteinprotein
interact
domain
f
protein
encompass
hydrophob
fusion
peptid
addit
shown
also
act
coreceptor
order
activ
mycobacteri
lipoarabinomannan
pathogenencod
ligand
bind
tlr
caus
conform
chang
tlr
dimer
lead
recruit
cytosol
tir
domaincontain
adapt
protein
intracellular
tir
domain
tlr
main
adapt
protein
includ
tir
ap
also
known
mal
trif
also
known
tram
also
known
pathway
activ
tlr
except
engag
trif
tlr
activ
trifdepend
signal
pathway
intern
endosom
plasma
membran
facilit
induct
trif
signal
pathway
tirap
origin
thought
act
bridg
recruit
tram
recruit
trif
review
howev
recent
work
kagan
colleagu
suggest
tirap
promiscu
fifth
member
tir
adapt
group
sarm
interact
trif
neg
regul
signal
propos
sixth
adapt
bcap
tirlik
domain
modul
bcell
activ
tlr
engag
tlr
ligand
caus
conform
chang
recruit
adapt
tirtir
interact
lead
activ
cascad
signal
transduct
molecul
includ
irak
among
other
lead
phosphoryl
inhibitor
kinas
releas
transcript
factor
nucleu
induc
express
proinflammatori
gene
tnfa
review
pathway
also
result
activ
mapk
contrast
trifmedi
signal
pathway
involv
delay
activ
robust
activ
import
transcript
factor
induct
type
ifn
primarili
macrophag
ifninduc
gene
endosom
tlr
engag
pathway
activ
lead
product
high
level
type
ifn
review
taken
togeth
activ
mapk
trigger
tlr
plasma
membran
endosom
wherea
tlrinduc
activ
initi
endosom
activ
tlr
signal
culmin
express
mani
secret
cytokin
ifn
chemokin
well
caus
cell
differenti
prolifer
apoptosi
tlrligand
interact
complex
outcom
depend
mani
factor
differenti
express
tlr
among
differ
cell
type
cell
typespecif
signal
pathway
usag
vari
adapt
differ
tlr
discoveri
vaccinia
viru
protein
antagonist
tlr
signal
sensor
rsv
f
protein
first
prompt
idea
viral
compon
may
serv
tlr
ligand
definit
discoveri
recogn
dsrna
major
compon
mani
virus
reveal
role
tlr
antivir
respons
accumul
evid
suggest
mani
virus
activ
innat
immun
tlr
lead
protect
immun
order
resolv
viral
infect
endosom
tlr
recogn
viral
nucleic
acid
tlr
plasma
membran
detect
viral
protein
either
intact
organ
releas
extracellular
environ
howev
viral
infect
activ
tlr
pathway
augment
sever
diseas
review
complex
set
prr
within
outsid
tlr
famili
order
mount
effect
immun
respons
cooper
complex
interplay
differ
receptor
may
result
complementari
synergist
effect
modul
innat
adapt
immun
review
sinc
interact
beyond
scope
articl
outcom
tlr
interact
virus
discuss
see
tabl
particular
describ
studi
aim
develop
tlrbase
therapi
either
form
agonist
antagonist
order
establish
antivir
respons
circumv
tlrmediat
detriment
immun
respect
summar
tabl
furthermor
mani
virus
evolv
defens
mechan
order
escap
sabotag
surveil
innat
immun
system
benefit
promin
exampl
viral
subvers
hcmv
glycoprotein
b
h
hcv
trigger
pdc
apoptosi
order
establish
viral
persist
core
protein
ebv
utpas
hsv
dual
report
protect
harm
inflammatori
respons
glycoprotein
ghgl
gb
rotaviru
rsv
protect
mcmv
protect
mcmv
protect
protect
emcv
protect
coxsackieviru
protect
polioviru
protect
rotaviru
protect
hcv
protect
dengu
viru
protect
hanta
viru
protect
ptv
harm
inflammatori
respons
influenza
harm
inflammatori
respons
vaccinia
harm
inflammatori
respons
wnv
dual
report
harm
inflammatori
respons
protect
vsv
glycoprotein
g
influenza
harm
inflammatori
respons
sarscov
protect
pneumonia
viru
mice
protect
hcv
protect
wnv
dual
report
protect
chang
suscept
hiv
heighten
immun
activ
postul
faster
diseas
progress
protect
mcmv
protect
pox
viru
protect
hiv
polymorph
influenc
clinic
cours
infect
pfizer
agonist
develop
treatment
hcv
phase
earli
termin
studi
oral
prodrug
isatoribin
anadi
pharma
agonist
develop
treatment
hcv
phase
suspend
oral
prodrug
isatoribin
anadi
pharma
agonist
develop
treatment
hcv
phase
iia
trial
agonist
identifi
oral
activ
ifn
induc
mice
monkey
experiment
preclin
gilead
scienc
agonist
develop
treatment
hbv
hcv
phase
ii
recruit
rna
antagonist
reduc
ifn
cytokin
product
agonisttr
cell
mice
experiment
preclin
oligonucleotidebas
antagonist
antagonist
inhibit
signal
pathway
induct
broad
rang
cytokin
murin
human
cellbas
assay
vivo
mice
nonhuman
primat
viper
peptid
deriv
vaccinia
protein
show
potent
inhibit
pathway
target
mal
tram
adapt
molecul
similarli
strategi
target
receptoradapt
interact
design
protein
domain
peptid
peptidomimet
inhibitor
repres
potenti
approach
inhibit
downstream
assembl
function
signal
complex
order
control
inflammatori
diseas
sepsi
review
typic
function
heterodim
shown
recogn
viral
protein
measl
viru
hemagglutinin
protein
human
cmv
glycoprotein
b
h
hcv
core
protein
ebv
utpas
hsv
glycoprotein
ghgl
gb
rotaviru
use
knockout
mice
shown
activ
pathway
leukocyt
import
induct
cytokin
respons
rsv
control
viral
replic
vivo
moreov
neutrophil
migrat
dendrit
cell
dc
activ
lung
rsvinfect
anim
depend
activ
mice
show
higher
viral
load
mous
cmv
mcmv
reduc
nk
cell
recruit
spleen
liver
decreas
type
ifn
secret
compar
wildtyp
mice
studi
show
role
sens
vaccinia
viru
infect
demonstr
product
proinflammatori
cytokin
mediat
wherea
secret
ifn
independ
contrari
role
induct
proinflammatori
cytokin
chemokin
provoc
studi
report
sens
mcmv
vaccinia
viru
particl
special
inflammatori
monocyt
induc
type
ifn
requir
intern
pathway
activ
role
hsv
infect
less
clear
conflict
report
show
either
protect
role
along
brain
infect
report
inflammatori
respons
caus
lethal
enceph
patient
chronic
hcv
infect
shown
hcv
core
protein
induc
monocyt
via
caus
decreas
releas
plasmacytoid
dc
pdc
trigger
pdc
apoptosi
provid
possibl
basi
viral
persist
synthet
lipoprotein
deriv
mycoplasma
salivarium
recogn
vagin
appli
shown
creat
antiherpet
environ
higher
challeng
dose
mice
also
induc
signific
resist
infect
human
vagin
epitheli
cell
cultur
character
nucleic
acidsens
tlr
recogn
infect
dsrna
ssrna
dna
virus
review
activ
lead
trifmedi
induct
proinf
lammatori
cytokin
chemokin
type
ifn
activ
transcript
factor
variou
vivo
vitro
studi
establish
protect
role
mani
viral
infect
defici
render
mice
hypersuscept
infect
dna
virus
mcmv
mice
lack
show
higher
viral
load
decreas
product
type
ifn
compar
wildtyp
mice
similar
find
report
mice
infect
variou
rna
virus
includ
encephalomyocard
viru
coxsackieviru
polioviru
rotaviru
accumul
evid
show
predisposit
enceph
children
born
defici
signal
pathway
shown
requir
ifn
respons
hcv
dengu
viru
limit
replic
virus
vitro
furthermor
hanta
viru
infect
cell
result
express
antivir
gene
wherea
knockdown
led
increas
viral
replic
contrast
protect
role
virus
certain
viral
infect
elicit
immun
harm
host
exampl
mice
refractori
infect
exhibit
reduc
patholog
caus
virus
punta
toro
viru
influenza
vaccinia
viru
compar
wildtyp
mice
data
indic
increas
product
inflammatori
respons
caus
damag
wildtyp
mice
compar
mice
west
nile
viru
wnv
studi
role
inconsist
futur
scienc
group
wwwfuturemedicinecom
one
studi
mediat
wnv
lethal
anoth
activ
protect
wnv
therefor
agonist
antagonist
may
act
effect
antivir
therapi
depend
context
discuss
section
agonist
signal
activ
synthet
dsrna
agonist
polyriboinosin
polyribocyti
dylic
acid
poli
c
potent
immun
stimul
shown
induc
protect
immun
influenza
hbv
hiv
strain
coronavirus
intranas
treatment
poli
c
show
improv
surviv
diminish
viral
load
age
mice
infect
lethal
dose
sar
coronaviru
addit
poli
c
activ
multipl
element
innat
adapt
immun
includ
induct
ifn
proinflammatori
cytokin
chemokin
matur
dc
nk
cell
cytotox
virusspecif
tcell
respons
cytoplasm
rlr
sensor
rigi
thu
poli
c
show
potenti
adjuv
dctarget
vaccin
design
induc
tcellmedi
immun
clinic
develop
poli
c
u
ampligen
hemispherx
biopharma
pa
usa
develop
substitut
uridyl
acid
molar
ratio
synthesi
polycytidyl
acid
strand
poli
c
u
superior
safeti
profil
maintain
benefici
activ
parent
poli
c
term
induc
innat
immun
respons
unlik
poli
c
poli
c
u
therapi
fail
protect
mice
lethal
punta
toro
viru
infect
also
fail
produc
ifn
indic
poli
c
u
signal
poli
c
u
develop
treatment
hiv
influenza
flumist
medimmun
llc
md
usa
clinic
trial
chronic
fatigu
syndrom
hbv
hcv
infect
poli
c
stabil
polyllysin
carboxymethylcellulos
known
polyiclc
hiltonol
oncovir
inc
washington
dc
usa
studi
mice
suggest
polyiclc
liposomeencapsul
polyiclc
safe
provid
broadspectrum
protect
season
highli
pathogen
avian
influenza
virus
well
rsv
sar
viru
howev
cotton
rat
model
rsv
influenza
infect
intranas
administr
antivir
dose
polyiclc
induc
lung
inflamm
compar
transcript
analysi
upon
subcutan
administr
polyiclc
indic
induc
innat
immun
respons
similar
magnitud
live
viral
vaccin
human
variou
ongo
complet
clinic
trial
use
polyiclc
alon
vaccin
demonstr
safeti
efficaci
hiv
vaccin
trial
ongo
oncovir
inc
dalton
pharma
servic
canada
pika
newbiom
pika
pte
ltd
singapor
anoth
chemic
stabil
analog
poli
c
demonstr
potent
adjuv
enhanc
cellular
humor
immun
respons
hepat
b
antigen
addit
pika
shown
reduc
viral
load
significantli
lung
mice
infect
varieti
influenza
virus
hyperact
respons
certain
viral
infect
trigger
sens
lead
advers
effect
thu
strategi
prevent
patholog
use
antagonist
report
ssdna
oligonucleotid
odn
effici
block
uptak
poli
c
cell
reduc
poli
c
induc
cytokin
human
epitheli
cell
peripher
blood
mononuclear
cell
pbmc
dc
intranas
administr
ssdna
odn
inhibit
poli
c
induc
cytokin
releas
nasal
secret
cynomolgu
macaqu
find
provid
support
novel
modal
prevent
manag
inflammatori
condit
aggrav
activ
first
identifi
lp
receptor
also
first
tlr
shown
detect
viral
pamp
kurtjon
colleagu
show
sens
rsv
membranebound
f
protein
lead
cytokin
product
subsequ
demonstr
mice
challeng
rsv
impair
nk
cell
function
express
viral
clearanc
compar
wildtyp
mice
increas
risk
sever
rsv
bronchiol
symptomat
rsv
infect
highrisk
infant
young
children
rsv
f
protein
shown
interact
coreceptor
ntermin
domain
antagonist
rhodobact
sphaeroid
lp
synthet
eritoran
eisai
inc
nj
usa
show
signific
reduct
rsv
f
proteinmedi
activ
transfect
express
dosedepend
manner
eritoran
shown
inhibit
signal
pathway
bind
hydrophob
pocket
preclud
interact
activ
ligand
lp
advanc
design
safe
efficaci
vaccin
continu
prime
goal
global
public
health
major
vaccin
prepar
compos
antigen
interest
adjuv
togeth
gener
faster
stronger
longlast
immun
respons
immun
antigen
alon
year
aluminum
hydroxid
alum
vaccin
adjuv
approv
licens
human
use
worldwid
due
safeti
lack
side
effect
alum
effect
boost
antibodi
respons
howev
repeat
administr
vaccin
requir
moreov
alum
tend
gener
antiparasit
respons
rather
antivir
antibacteri
respons
review
current
much
effort
still
dedic
develop
new
adjuv
establish
protect
immun
fewer
vaccin
gener
durabl
antibodi
cytotox
tcell
respons
consequ
agonist
develop
immunomodul
adjuv
monophosphoryl
lipid
mpl
chemic
modifi
deriv
salmonella
minnesota
lp
approv
use
gener
good
adjuv
activ
approxim
inflammatori
toxic
induc
parent
molecul
lp
basi
mpl
adjuv
activ
entir
understood
rel
weak
agonist
suggest
exhibit
trif
bia
howev
latter
attribut
controversi
yet
confirm
underli
adjuv
properti
adjuv
compos
mpl
alum
known
glaxosmithklin
uk
licens
use
vaccin
hpv
cervarix
hbv
fendrix
combin
mpl
class
adjuv
emuls
saponin
liposom
alreadi
test
human
yet
licens
use
review
addit
mani
novel
adjuv
target
advanc
development
stage
either
alon
combin
adjuv
review
mpl
shown
modul
innat
immun
respons
directli
order
improv
magnitud
durat
adapt
immun
respons
vaccin
antigen
mpl
coadminist
differ
rsv
vaccin
prepar
anim
model
order
gener
safe
immun
respons
upon
subsequ
rsv
infect
earli
human
clinic
trial
formalininactiv
rsv
firsv
vaccin
caus
exacerb
diseas
upon
natur
infect
vaccine
includ
two
death
subsequ
sever
rsv
subunit
vaccin
liveattenu
rsv
vaccin
propos
subunit
rsv
vaccin
prime
excess
respons
develop
vaccineenhanc
diseas
upon
natur
rsv
infect
attenu
vaccin
often
show
residu
virul
poor
immunogen
genet
instabl
review
use
ident
lot
firsv
fail
vaccin
trial
cotton
rat
model
shown
faith
recapitul
patholog
induc
rsv
infect
lot
children
upon
subsequ
rsv
challeng
cotton
rat
immun
firsv
combin
mpl
show
dramat
decreas
lung
patholog
compar
firsv
alon
chang
lung
viral
replic
despit
slight
increas
neutral
antibodi
titer
furthermor
immun
cotton
rat
firsv
plu
mpl
show
strong
inhibit
express
cytokin
chemokin
gene
respons
subsequ
rsv
challeng
thu
inclus
mpl
firsv
vaccin
diminish
express
aberr
cytokin
storm
hallmark
vaccineenhanc
diseas
upon
rsv
infect
similarli
addit
mpl
reconstitut
nucleocapsiddeplet
rsv
membran
virosom
demonstr
gener
immun
respons
without
prime
enhanc
respiratori
diseas
furthermor
mucos
intranas
administr
rsvmpl
virosom
shown
safe
protect
live
viru
challeng
mice
cotton
rat
vaccin
base
futur
scienc
group
wwwfuturemedicinecom
recombin
purifi
anchorless
rsv
f
protein
formul
mpl
administ
heterolog
primeboost
strategi
intranas
follow
intraderm
boost
show
enhanc
protect
rsv
without
aberr
lung
histopatholog
induct
cytokin
storm
antagonist
lp
gramneg
bacteria
potent
agonist
solubl
membraneassoci
nonmembranespan
protein
requir
coreceptor
optim
lpsinduc
pathway
activ
lipid
toxic
moieti
lp
highli
conserv
among
endotoxin
ideal
target
drug
develop
firstgener
lipid
antagonist
deriv
structur
rhodobact
capsulatu
endotoxin
eisai
research
institut
boston
usa
demonstr
protect
experiment
model
endotoxemia
lethal
infect
e
coli
secondgener
lp
antagonist
eritoran
tetrasodium
also
develop
eisai
inc
synthet
lipid
analog
r
sphaeroid
first
shown
qureshi
colleagu
block
lpsinduc
lethal
develop
treatment
gramneg
sepsi
inhibit
lpsinduc
cytokin
vitro
experiment
anim
model
crystallograph
structur
analysi
complex
show
four
acyl
chain
occupi
nearli
solventaccess
volum
deep
hydrophob
pocket
prevent
bind
toxic
lipid
prerequisit
lpsmediat
activ
advanc
phase
iii
clinic
trial
call
access
howev
show
signific
benefit
sever
septic
patient
stimul
tlr
certain
viral
pathogen
shown
result
detriment
immun
host
demonstr
harm
inflammatori
respons
influenza
viru
infect
gener
hostderiv
oxid
phospholipid
reactiv
oxygen
speci
due
chemic
microbi
insult
shown
stimul
potent
inflamm
lead
develop
acut
lung
injuri
furthermor
mice
highli
resist
influenzainduc
lethal
basi
data
shirey
et
al
propos
block
signal
antagonist
eritoran
would
protect
influenza
infect
eritoran
found
decreas
influenzainduc
lethal
significantli
mice
even
administ
day
postviru
infect
improv
lung
patholog
clinic
symptom
decreas
lung
viral
titer
influenzainduc
cytokin
oxid
phospholipid
express
observ
eritorantr
mice
cotton
rat
compar
placebotr
group
find
rais
possibl
util
antagonist
order
manag
inflamm
associ
influenza
possibl
viral
infect
eritoran
also
effect
cotton
rat
challeng
nonadapt
human
influenza
viru
recent
studi
show
block
lpsand
e
coliinduc
lethal
mice
suggest
may
target
signal
cyclic
antimicrobi
peptid
express
nonhuman
primat
review
peptid
chimera
form
headtotail
splice
nonapeptid
deriv
two
separ
precursor
human
stop
codon
preclud
express
pseudogen
revers
engin
synthes
name
retrocyclin
retrocyclin
potent
antimicrobi
antitoxin
properti
broad
spectrum
bacteria
fungi
virus
includ
influenza
hiv
hsv
review
interestingli
antiinflammatori
properti
recent
confirm
retrocyclin
block
lpsinduc
activ
signal
intermedi
gene
express
data
shown
impli
retrocyclin
may
also
interfer
virusor
dampinduc
signal
mechan
action
open
new
possibl
treatment
multipathogen
infect
relat
function
detect
gurich
aurich
ssrna
sequenc
viral
genom
influenza
vesicular
stomat
viru
coxsacki
b
viru
coronaviru
flavivirus
hcv
wnv
review
primarili
express
pdc
extent
b
cell
monocyt
macrophag
wherea
mostli
express
monocyt
macrophag
myeloid
dc
mous
mostli
report
review
patel
shirey
pletneva
et
al
futur
scienc
group
nonfunct
howev
paper
shown
murin
activ
combin
imidazoquinolin
polyt
oligodeoxynucleotid
vaccinia
viru
dna
activ
pdc
respons
product
high
level
type
ifn
consid
major
antivir
mechan
human
sar
coronaviru
pneumonia
viru
mice
hcv
howev
case
mous
retroviru
infect
sens
viru
upon
cellular
entri
stimul
virusneutr
antibodi
crucial
viral
clearanc
studi
report
role
wnv
infect
differ
significantli
one
studi
show
protect
role
intraperiton
wnv
infect
mice
wherea
anoth
studi
demonstr
chang
suscept
intraderm
viru
infect
wildtyp
knockout
mice
find
indic
factor
viru
dose
passag
histori
rout
administr
like
crucial
defin
role
tlr
experiment
viral
infect
recent
studi
present
evid
women
chronic
infect
hiv
show
heighten
level
respons
activ
pdc
activ
cell
compar
level
seen
men
increas
hiv
immun
activ
postul
one
reason
faster
diseas
progress
women
hypothes
modul
activ
pdc
may
offer
novel
mechan
reduct
aid
progress
agonist
activ
imidazoquinolin
famili
synthet
lowmolecularweight
compound
strong
antivir
activ
imiquimod
resiquimod
synthet
molecul
differenti
modul
pathway
term
target
cell
select
cytokin
induct
profil
exampl
human
pbmc
agonist
shown
effect
induc
type
ifn
ifnregul
chemokin
agonist
effect
induc
proinflammatori
cytokin
chemokin
imiquimod
aldara
origin
develop
pharmaceut
mn
usa
introduc
topic
treatment
genit
perian
wart
caus
hpv
infect
initi
imiquimod
shown
immun
respons
modifi
produc
type
ifn
cytokin
later
report
due
activ
imiquimod
approv
therapeut
treatment
extern
genit
wart
precancer
actin
keratosi
basal
cell
carcinoma
shown
mix
efficaci
treatment
hsv
infect
clinic
studi
resiquimod
mix
agonist
use
topic
treatment
genit
hsv
oral
hcv
infect
howev
result
show
lack
adequ
efficaci
sever
side
effect
higher
dose
resiquimod
treatment
suppress
hiv
replic
cultur
human
monocyt
anoth
agonist
report
restor
defect
cytokin
secret
myeloid
dc
hivinfect
pregnant
women
newborn
treatment
significantli
enhanc
gcsf
secret
pbmc
suggest
possibl
therapeut
role
treatment
neutropenia
chronic
hcv
patient
variou
agonist
isatoribin
advanc
clinic
studi
formerli
known
potent
agonist
order
develop
treatment
hcv
pfizer
ny
usa
conduct
studi
evalu
safeti
toler
healthi
volunt
induc
biomark
immun
type
ifn
respons
dosedepend
manner
howev
two
subject
receiv
higher
dose
experienc
influenzalik
symptom
hypotens
lymphopenia
studi
termin
earli
model
simul
techniqu
use
predict
efficaci
safeti
hcv
patient
achiev
proofofconcept
studi
criteria
model
simul
suggest
compound
discontinu
hcv
treatment
select
agonist
guanosin
analog
ie
isatoribin
deriv
develop
anadi
pharmaceut
ca
usa
intraven
treatment
hcv
patient
isatoribin
result
signific
reduct
plasma
hcv
rna
oral
prodrug
develop
order
avoid
side
effect
isatoribin
especi
gi
tract
preliminari
result
show
well
toler
oral
administr
increas
plasma
level
isatoribin
effect
reduc
hcv
rna
futur
scienc
group
wwwfuturemedicinecom
plasma
infect
patient
howev
due
toxic
observ
preclin
anim
studi
trial
suspend
subsequ
oral
prodrug
isatoribin
show
effici
induct
type
ifn
prove
safe
well
toler
preclin
studi
doubleblind
placebocontrol
studi
patient
infect
chronic
hcv
show
dosedepend
increas
ifn
respons
decreas
serum
hcv
rna
repeat
administr
chronic
hcv
patient
result
transient
reduct
blood
myeloid
dc
pdc
number
increas
serum
level
patient
show
reduc
serum
hcv
rna
upon
drug
treatment
seri
deriv
structur
relat
isatoribin
report
novel
ifn
induc
among
deriv
identifi
oral
activ
ifn
induc
mice
monkey
potenc
superior
resiquimod
gilead
scienc
ca
usa
potent
select
oral
activ
agonist
show
strong
reduct
serum
liver
hbv
dna
along
ifninduc
innat
respons
hbvinfect
chimpanze
doubleblind
placebocontrol
studi
healthi
volunt
shown
well
absorb
well
toler
induct
cytokin
chemokineand
ifnstimul
gene
achiev
dose
approxim
mg
well
dose
known
caus
advers
clinic
event
due
encourag
find
effort
progress
order
develop
treatment
hbv
hcv
antagonist
play
key
role
sens
viral
rna
gener
antivir
immun
howev
excess
tlr
activ
viral
infect
recognit
selfrna
may
gener
detriment
immun
respons
host
therefor
effort
gener
antagonist
prime
import
end
report
rna
significantli
reduc
product
agonisttr
murin
dc
human
pbmc
mice
thu
consid
potent
antagonist
recent
synthesi
evalu
odnbas
antagonist
contain
anabinog
modif
immunostimulatori
motif
immunoregulatori
motif
report
antagonist
compound
show
inhibit
signal
pathway
induct
broad
rang
cytokin
murin
human
cellbas
assay
vivo
mice
nonhuman
primat
indic
novel
possibl
use
antagonist
inflammatori
autoimmun
diseas
recogn
unmethyl
cpg
odn
present
microbi
dna
absent
vertebr
genom
constitut
express
pdc
b
cell
activ
pdc
produc
larg
amount
type
ifn
control
viral
replic
erad
infect
cell
antivir
immun
report
gener
respons
infect
hsv
mcmv
adenoviru
poxviru
hiv
infect
singlenucleotid
polymorph
associ
rapid
progress
infect
agonist
agonist
synthet
cpg
odn
cpg
natur
cpg
odn
suscept
serum
cellular
nucleas
due
phosphodiest
backbon
howev
cpgcontain
phosphorothio
odn
nucleaseresist
wide
exploit
clinic
use
cpg
odn
via
activ
primarili
stimul
immun
respons
thu
cpg
odn
strong
immunostimul
wide
test
effect
vaccin
adjuv
influenza
hiv
varieti
malign
review
hivinfect
patient
reduc
b
cell
caus
impair
bcell
respons
wherea
cpg
odn
enhanc
prolif
effector
respons
b
cell
hiv
patient
coley
pharmaceut
usa
promis
development
stage
treatment
chronic
viral
infect
hcv
subcutan
administr
healthi
volunt
well
toler
show
immunostimulatori
characterist
low
advers
effect
multicent
phase
ib
trial
hcvposit
patient
induc
dosedepend
increas
immun
activ
diminish
hcv
rna
review
patel
shirey
pletneva
et
al
futur
scienc
group
level
support
use
treatment
chronic
hcv
immunomodulatori
odn
imo
idera
pharmaceut
usa
synthet
dna
structur
call
immunom
contain
dinucleotid
immunostimulatori
motif
cpr
rpg
r
synthet
analog
natur
base
imo
greater
metabol
stabil
induc
differ
cytokin
profil
depend
structur
sequenc
immunom
show
high
sustain
level
ifn
respons
nonhuman
primat
promis
antivir
effect
phase
clinic
trial
hcv
patient
idera
pharmaceut
anoth
secondgener
agonist
shown
stimul
higher
level
human
pbmc
firstgener
agonist
phase
ib
studi
hcv
patient
report
safe
well
toler
produc
signific
antivir
activ
base
dosedepend
ifn
respons
dynavax
technolog
co
ca
usa
sinc
discoveri
first
receptor
recogn
dsrna
signific
progress
made
understand
tlrmediat
immun
respons
follow
differ
viral
infect
knowledg
virusinduc
tlr
signal
pathway
led
develop
novel
therapeut
target
tlr
antivir
antiinflammatori
therapi
dynam
field
grow
rapidli
recent
year
approv
use
agonist
imiquimod
therapi
hpvinduc
genit
wart
agonist
mpl
adjuv
vaccin
hpv
hbv
success
exampl
translat
effort
addit
agonist
show
promis
result
treatment
viral
infect
howev
mani
challeng
exist
develop
new
tlrbase
antivir
target
importantli
interact
viru
tlr
signal
compon
complex
outcom
depend
tlr
viru
host
speci
case
vaccinia
viru
infect
respons
harm
immun
respons
prove
protect
mice
moreov
singl
ligand
sens
differ
tlr
depend
local
antigen
may
gener
overlap
redund
respons
case
mcmv
infect
impart
redund
function
ifn
product
pdc
vivo
case
redund
ligand
sens
tlr
taken
account
order
develop
singl
tlrtarget
treatment
strategi
infect
resolv
cooper
multipl
tlr
tlr
cooper
class
prr
exampl
requir
immun
overlap
gener
respons
mcmv
mice
mice
highli
refractori
influenza
infect
furthermor
coordin
recognit
rhinoviru
initi
via
later
rigi
requir
order
induc
antivir
respons
within
bronchial
epithelium
hsv
infect
sens
rlr
synerg
induc
type
ifn
product
observ
indic
complex
crosstalk
differ
tlr
tlr
famili
prr
exist
order
resolv
mediat
certain
viral
infect
utmost
import
us
understand
character
take
account
possibl
interact
tlr
famili
prr
order
design
appli
novel
target
tlr
efficaci
treatment
applic
anim
model
provid
primari
valuabl
inform
safeti
efficaci
molecular
mechan
select
drug
target
howev
tlr
target
show
import
speciesspecif
variat
effect
certain
drug
rsvinfect
balbc
mice
treat
polyiclc
show
significantli
reduc
inflamm
clinic
score
diseas
howev
contrast
murin
model
polyiclc
treatment
result
increas
patholog
rsv
infect
cotton
rat
addit
due
import
differ
tlr
signal
pathway
anim
model
human
mani
drug
test
encourag
result
anim
model
fail
show
much
effect
human
studi
natur
condit
tlrbase
immun
respons
pathogen
exposur
diversifi
basi
differ
cellular
distribut
variou
anatom
site
differenti
pattern
tlr
express
among
subset
dc
antigenpres
cell
thu
tlr
agonist
produc
differ
respons
basi
rout
administr
eg
contrari
intraven
futur
scienc
group
wwwfuturemedicinecom
administr
subcutan
cpg
induc
innat
immun
respons
differ
respons
tlr
ligand
administ
differ
rout
pose
challeng
opportun
develop
tlrbase
drug
vaccin
tlr
fundament
sensor
innat
immun
system
thu
activ
inhibit
tlr
pathway
therapeut
tlr
agonist
antagonist
may
caus
potent
harm
immun
activ
unwant
immunosuppress
moreov
difficult
predict
efficaci
offtarget
effect
larg
human
popul
end
phase
safeti
trial
therapeut
tlr
target
must
assess
shortand
longterm
effect
altern
dose
regimen
differenti
rout
administr
may
alter
efficaci
safeti
drug
question
addit
target
therapeut
drug
tolllik
receptor
tlr
one
largest
beststudi
famili
patternrecognit
receptor
innat
immun
system
tlr
recogn
pathogenand
dangerassoci
molecular
pattern
activ
downstream
signal
cascad
order
induc
proinflammatori
cytokin
antivir
type
interferon
transcript
factor
respect
tlrmediat
respons
orchestr
develop
longlast
pathogenspecif
adapt
immun
respons
tlr
plasma
membran
detect
viral
protein
releas
extracellular
environ
endosom
tlr
recogn
viral
nucleic
acid
activ
trigger
tlr
plasma
membran
endosom
wherea
tlrinduc
activ
initi
endosom
activ
tlr
signal
viral
ligand
establish
primarili
antivir
respons
howev
certain
viral
infect
develop
tlrmediat
detriment
immun
host
mani
virus
evolv
defens
mechan
escap
surveil
tlrmediat
innat
immun
system
drug
target
tlr
offer
novel
opportun
prevent
intervent
virusinduc
infecti
diseas
either
directli
improv
vaccin
efficaci
adjuv
compos
agonist
monophosphoryl
lipid
licens
use
vaccin
hpv
hbv
vaccin
rsv
formul
monophosphoryl
lipid
enhanc
protect
rsv
without
aberr
lung
histopatholog
anim
studi
agonist
imiquimod
approv
treatment
genit
wart
caus
hpv
agonist
show
promis
result
treatment
viral
infect
hiv
influenza
hbv
hcv
effort
develop
tlr
antagonist
treatment
virusinduc
harm
inflammatori
respons
still
earli
develop
stage
antagonist
eritoran
drug
origin
develop
treatment
sepsi
show
encourag
result
regard
prevent
influenzainduc
inflamm
anim
studi
target
tlr
drug
may
caus
potent
harm
immun
activ
unwant
immunosuppress
develop
mani
compound
termin
due
safeti
concern
offtarget
effect
earli
clinic
studi
garzinodemo
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
write
assist
util
product
manuscript
relev
tissu
organ
may
benefici
limit
offtarget
effect
furthermor
recent
mous
cotton
rat
data
eritoran
antagonist
develop
manag
sepsi
show
promis
result
regard
interven
inflamm
associ
influenza
infect
open
door
possibl
treatment
infecti
agent
sens
damp
initi
cytokin
storm
summari
develop
tlrtarget
therapi
form
agonist
antagonist
offer
excit
promis
new
possibl
prevent
virusinduc
infecti
diseas
manag
virusinduc
harm
inflammatori
respons
first
report
demonstr
therapeut
potenti
antagonist
prevent
influenzainduc
inflammatori
respons
